Research programme: hypophosphatasia haematopoietic stem cell therapies - Rampart Bioscience
Latest Information Update: 31 Mar 2023
At a glance
- Originator Rampart Bioscience
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Hypophosphatasia